Cipla recalls Solifenacin Succinate tablets in US over manufacturing issues

Published On 2021-07-26 08:00 GMT   |   Update On 2021-07-26 08:25 GMT
Advertisement

New Delhi: Drug major Cipla is recalling 7,228 bottles of Solifenacin Succinate tablets, a medicine used to treat overactive bladder, in the US market due to manufacturing issues.

As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), the Mumbai-based company is recalling 10 mg, 30-count bottles in the US.

The recalled batches were produced at the company''s Goa-based plant and later shipped to its New Jersey-based arm Cipla USA Inc.

Advertisement

The US health regulator noted that the company is recalling the 7,228 bottles due to "CGMP (current good manufacturing practices) deviations".

Cipla initiated the recall on June 10 this year and the USFDA has classified it as a Class II recall.

As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

In January this year, the Mumbai-based drug firm had recalled over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market.

The drug firm manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied it to its New Jersey-based subsidiary.

Read also: Philips ventilator recall classified as most serious by USFDA

The USFDA cited "cross-contamination with other products" as the reason for the company recalling the product.

Cipla is one of the largest generic drug makers with over 1,500 products in 65 therapeutic categories available in over 50 dosage forms.

Read also: Cipla arm's oral liquid dosage, nasal product unit acquired by Rubicon Research




Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News